Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ptc Therapeutics (PTCT) Tax Provisions (2016 - 2025)

Ptc Therapeutics has reported Tax Provisions over the past 11 years, most recently at -$15.4 million for Q4 2025.

  • Quarterly results put Tax Provisions at -$15.4 million for Q4 2025, down 601.28% from a year ago — trailing twelve months through Dec 2025 was $2.7 million (down 89.82% YoY), and the annual figure for FY2025 was $2.7 million, down 89.82%.
  • Tax Provisions for Q4 2025 was -$15.4 million at Ptc Therapeutics, up from -$39.0 million in the prior quarter.
  • Over the last five years, Tax Provisions for PTCT hit a ceiling of $63.3 million in Q1 2025 and a floor of -$39.0 million in Q3 2025.
  • Median Tax Provisions over the past 5 years was $469500.0 (2021), compared with a mean of -$1.5 million.
  • Peak annual rise in Tax Provisions hit 972.06% in 2022, while the deepest fall reached 49602.78% in 2022.
  • Ptc Therapeutics' Tax Provisions stood at $4.7 million in 2021, then surged by 198.26% to $13.9 million in 2022, then crashed by 109.06% to -$1.3 million in 2023, then crashed by 74.03% to -$2.2 million in 2024, then crashed by 601.28% to -$15.4 million in 2025.
  • The last three reported values for Tax Provisions were -$15.4 million (Q4 2025), -$39.0 million (Q3 2025), and -$6.2 million (Q2 2025) per Business Quant data.